RASSF4 as A Potential Drug Target (G83937)

Target Name: RASSF4

NCBI ID: G83937

RASSF4

RASSF4 as A Potential Drug Target

RASSF4 (RNA-associated protein of 4 kDa) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. RASSF4 is a key regulator of gene expression and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.

The discovery of RASSF4 as a potential drug target comes from a study by the Dunham group at the University of California, San Diego, which identified RASSF4 as a key regulator of the expression of the IL-6 gene. The IL-6 gene is a well-established cancer-promoting gene that has been linked to various diseases, including cancer, autoimmune diseases, and obesity.

Subsequent studies have shown that RASSF4 can be regulated by various signaling pathways, including TGF-閻???, NF-kappa-B, and PI3K/AKT. These signaling pathways are involved in cell proliferation, survival, and angiogenesis, and have been implicated in the development and progression of various diseases.

Drug targeting RASSF4

The identification of RASSF4 as a potential drug target has led to a great deal of interest in the development of new therapies for various diseases. One of the main advantages of targeting RASSF4 is its small size, which allows for efficient delivery to the target cell. Additionally, RASSF4 is highly expressed in various tissues and cells, which makes it an attractive target for small molecules.

Currently, several companies have entered the drug development process for RASSF4-based therapies. These therapies are designed to inhibit the activity of RASSF4 and its downstream targets, leading to the inhibition of cell proliferation and the inhibition of the signaling pathways involved in cell survival and angiogenesis.

One of the companies that has been particularly active in the development of RASSF4-based therapies is Exact Sciences, which has developed a drug called Cottington, which is currently in clinical trials for the treatment of various types of cancer. Cottington is designed to inhibit the activity of RASSF4 and its downstream targets, leading to the inhibition of cell proliferation and the inhibition of the signaling pathways involved in cell survival and angiogenesis.

Another company that is developing RASSF4-based therapies is focused on oncology, Alcentive BioScience. The company has developed a drug called Rassf4 inhibitor, which is currently in preclinical studies for the treatment of various types of cancer. The Rassf4 inhibitor is designed to inhibit the activity of RASSF4 and its downstream targets, leading to the inhibition of cell proliferation and the inhibition of the signaling pathways involved in cell survival and angiogenesis.

Meanwhile, in cardiovascular diseases, some studies have shown that RASSF4 may be a potential drug target by regulating the expression of genes involved in the inflammatory response and fibrosis. Therefore, there is a growing interest in the development of RASSF4-based therapies for cardiovascular diseases.

In conclusion, RASSF4 is a non-coding RNA molecule that has been shown to be involved in many cellular processes, including cell growth, apoptosis, and inflammation. In recent years, studies have found that RASSF4 may be a potential drug target in tumors, autoimmune diseases, and obesity. Currently, several pharmaceutical companies have developed RASSF4-based therapies, which aim to inhibit the activity of RASSF4 and its downstream targets, thereby inhibiting cell proliferation and inhibiting cell survival and proliferation involved in cell survival and proliferation signaling pathways.

Protein Name: Ras Association Domain Family Member 4

Functions: Potential tumor suppressor. May act as a KRAS effector protein. May promote apoptosis and cell cycle arrest

The "RASSF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASSF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets